Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 370 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo ophthalmic solution Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance

NCT04831047
View directory record Official record
Conditions
Ptosis, Eyelid, Conjunctiva Inflamed, Eye Manifestations
Interventions
Oxymetazoline hydrochloride 0.1% ophthalmic solution, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects

NCT01675609
View directory record Official record
Conditions
Ocular Redness
Interventions
Placebo, Brimonidine tartrate 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
40 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

TXA in Spinal Fusion

NCT04272606
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Tranexamic Acid, Saline Solution, Visual Acuity Exam, 3 Minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)
Drug · Diagnostic Test
Lead sponsor
Catherine R. Olinger
Other
Eligibility
18 Years to 90 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

NCT02207491
View directory record Official record
Conditions
Ocular Hypertension, Open-angle Glaucoma
Interventions
Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
Drug · Other
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
411 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances

NCT04638660
View directory record Official record
Conditions
Dim Light Vision Disturbances
Interventions
Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo)
Drug
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
17
States / cities
Newport Beach, California • Petaluma, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1Phase 2 Interventional

Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma

NCT00753168
View directory record Official record
Conditions
Glaucoma, Open-Angle, Ocular Hypertension
Interventions
OT-730 ophthalmic solution, timolol maleate ophthalmic solution, OT-730 placebo
Drug
Lead sponsor
Othera Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Artesia, California • Roswell, Georgia • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2009 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia

NCT05665387
View directory record Official record
Conditions
Presbyopia
Interventions
0.1% STN1013600 ophthalmic solution, 0.3% STN1013600 ophthalmic solution, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
47 Years to 55 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
12
States / cities
Glendale, California • Newport Beach, California • Morrow, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1 Interventional

A Multi-Center Study Subjects With Dry Eye Syndrome

NCT01745887
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
EBI-005-2
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Artesia, California • Ranchero Cordova, California • Torrence, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2013 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery

NCT00524264
View directory record Official record
Conditions
Cataract Extraction, Pain, Inflammation
Interventions
ketorolac
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2009 · Synced Oct 29, 2026, 11:23 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-ranging Study to Evaluate the Safety and Efficacy of UNR844 in Subjects With Presbyopia.

NCT04806503
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 55 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
12
States / cities
Laguna Hills, California • Newport Beach, California • Largo, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

NCT01212471
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Bromfenac Ophthalmic Solution A, Bromfenac Ophthalmic Solution B, Placebo Comparator
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Effectiveness of ST266 Ophthalmic Drops Compared to Placebo to Treat Allergic Conjunctivitis

NCT02978183
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
ST266, Saline (0.9% NaCl)
Biological · Drug
Lead sponsor
Noveome Biotherapeutics, formerly Stemnion
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Andover, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

NCT00518089
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Gatifloxacin 0.5% eye drops, placebo eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
1 Year and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Downey, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period

NCT00892970
View directory record Official record
Conditions
Blepharitis
Interventions
Azithromycin ophthalmic solution, 1%, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
33
States / cities
Little Rock, Arkansas • Artesia, California • Azusa, California + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

NCT04004507
View directory record Official record
Conditions
Decrease in Night Vision, Disturbance; Vision, Loss
Interventions
Phentolamine Mesylate Ophthalmic Solution 1%, Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)
Drug · Other
Lead sponsor
Opus Genetics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Lynbrook, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation

NCT03751098
View directory record Official record
Conditions
Mydriasis
Interventions
Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
Not listed
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2022 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 4 Interventional

A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis

NCT00655109
View directory record Official record
Conditions
Conjunctivitis, Allergic
Interventions
Olopatadine, Fluticasone, Saline, Artificial tears
Drug
Lead sponsor
Greiner, Jack V., OD DO PhD
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
North Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 9, 2008 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

NCT01134055
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, placebo, ranibizumab intravitreal injection
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2018 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Controlled Study of the Aqueous Humor Dynamics of AR-13324 Ophthalmic Solution in Healthy Adult Volunteers

NCT02406287
View directory record Official record
Conditions
Healthy Subjects
Interventions
Netarsudil (AR-13324) Ophthalmic Solution, Netarsudil (AR-13324) Ophthalmic Solution Placebo
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bedminster, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 13, 2016 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis

NCT00586664
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bepreve (bepotastine besilate ophthalmic solution) 1.5%, placebo comparator, Bepotastine Besilate Ophthalmic Solution 1.0%
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 29, 2026, 11:23 AM EDT
Recruiting Phase 4 Interventional

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

NCT05663684
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

NCT00538304
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
bimatoprost eye drops, placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 2 Interventional

Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery

NCT03180255
View directory record Official record
Conditions
Cataract, Anterior Chamber Inflammation, Pain, Postoperative
Interventions
Dexamethasone phosphate, Placebo
Combination Product · Other
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 21, 2018 · Synced Oct 29, 2026, 11:23 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725
View directory record Official record
Conditions
Post Surgical Ocular Inflammation
Interventions
TRS01 eye drops, Placebo eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Inglewood, California • Petaluma, California • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 29, 2026, 11:23 AM EDT